Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Overview for Request: cder_mpl1r_wp227

Request ID: cder_mpl1r_wp227_nsdp_v01

Request Description: In this report we examined counts of individuals who received Sinuva or Propel, both of which are mometasone furoate (MF) sinus stents, for the treatment of nasal polyps in the Sentinel Distributed Database (SDD). Additionally, we examined these individuals further on whether they had no record indicating the presence of glaucoma or cataracts in the six months prior to receiving the Sinuva MF sinus stent.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 11.4.0

Data Source: We distributed this query to 14 Sentinel Data Partners on November 17, 2022. The study period included data from January 1, 2016 through July 31, 2022. This report contains aggregated data from 14 DP, a subset of SDD. Data from Medicare patients having both fee-for-service medical coverage are included. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We identified individuals with incident use of Sinuva or Propel MF sinus stents. All individuals were required to have a record of nasal polyps within the six months prior to index, and depending on the cohort, individuals were excluded based on records for glaucoma, cataracts, or prior receipt of Sinuva or Propel MF sinus stents. Counts were stratified by age, sex, and year. The analyses characterized dispensing patterns by examining cumulative exposure episode durations, first exposure episode durations, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes. This is a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposure(s) of Interest: The exposures of interest were defined using National Drug Codes (NDCs), as well as Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), and Healthcare Common Procedure Coding System, Level II (HCPCS) codes. Please refer to Appendix B for a list of CPT-3, CPT-4, and HCPCS codes used to define exposures in this request. Refer to Appendix C for a list of generic and brand names of medical products used to define exposures in this request.

Cohort Eligibility Criteria: We defined index date for each patient as the date of the first dispensing of a MF stent of interest. We required members to be enrolled in health plans with medical and drug coverage in the 183 days prior to their index date in order to be included in the cohort; a gap in coverage of up to 45 days was allowed and treated as continuous enrollment. We created the following eight cohorts with the inclusion/exclusion criteria as described below:

1. Single Sinuva MF stent users with no prior use of Sinuva or Propel: Sinuva sinus stent dispensing and no evidence of a Sinuva or Propel sinus stent in the 183 days prior to the index dispensing
2. Single Sinuva MF stent users with no prior use of Sinuva or Propel and no Glaucoma: Sinuva sinus stent dispensing and no evidence of a Sinuva or Propel sinus stent and glaucoma in the 183 days prior to the index dispensing
3. Single Sinuva MF stent users with no prior use of Sinuva or Propel and no Cataracts: Sinuva stent dispensing and no evidence of a Sinuva or Propel sinus Stent and cataracts in the 183 days prior to the index dispensing
4. Single Sinuva MF stent users with no prior use of Sinuva: Sinuva stent dispensing and no evidence of Sinuva sinus stent in the 183 days prior to the index dispensing
5. Single Sinuva MF stent users with no prior use of Sinuva and no Glaucoma: Sinuva sinus stent dispensing and no evidence of Sinuva sinus stent and glaucoma in the 183 days prior to the index dispensing
6. Single Sinuva MF stent users with no prior use of Sinuva and no Cataracts: Sinuva sinus stent dispensing and no evidence of Sinuva sinus stent and cataracts in the 183 days prior to the index dispensing
7. Single Propel MF stent users: Propel sinus stent dispensing and no evidence of a Propel or Sinuva sinus stent in the 183 days prior to the index dispensing
8. Sinuva MF Repeat stent users: Sinuva MF Sinus Stent dispensing (no additional cohort criteria applied)

Overview for Request: cder_mpl1r_wp227
The following age groups were included in the cohorts: 0-1, 2-4, 5-9, 10-14, 15-18, 19-21, 22-44, 45-64 ,65-74 ,75+ years. We also required evidence of nasal polyps in the 183 days (six months) prior to the index dispensing. Please see Appendix D for a list of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) procedure and diagnosis codes used to define inclusion criteria in this request. See Appendix E for a list of CPT-3, CPT-4, HCPCS, ICD-9-CM, ICD-10-CM, and ICD-10-PCS codes used to define exclusion criteria in this request. See Appendix F for a list of generic and brand names of medical products used to define exclusion criteria in this request. **Limitations:** Algorithms to define exposures, inclusion, and exclusion criteria are imperfect and may result in misclassification. Therefore, data should be interpreted with this limitation in mind. **Notes:** Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).

Sentinel

Table of Contents

Table of Contents

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.
Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.
Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

- **Ambulatory Visit (AV) -** includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- **Emergency Department (ED) -** includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- **Inpatient Hospital Stay (IP) -** includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- **Non-Acute Institutional Stay (IS) -** includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- **Other Ambulatory Visit (OA) -** includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).
Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.
Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.
Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.
Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.
Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.
Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.
Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.
Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.
Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).
Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."
Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.
Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of Single Sinuva MF Stent Users with no prior use of Propel or Sinuva in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Single Sinuva MF Stent Users with no prior use of Propel or Sinuva	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Unique patients	1,401	N/A
Demographic Characteristics		
Age (years)	57.3	12.5
Age		
0-1 years	0	0.0%
2-4 years	0	0.0%
5-9 years	0	0.0%
10-14 years	*****	*****
15-18 years	*****	*****
19-21 years	*****	*****
22-44 years	306	21.8%
45-64 years	462	33.0%
65-74 years	429	30.6%
≥ 75 years	169	12.1%
Sex		
Female	560	40.0%
Male	841	60.0%
Race[2]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	698	49.8%
White	650	46.4%
Hispanic origin		
Yes	*****	*****
No	577	41.2%
Unknown	804	57.4%
Year		
2016	0	0.0%
2017	0	0.0%
2018	*****	*****

Table 1a. Aggregated Characteristics of Single Sinuva MF Stent Users with no prior use of Propel or Sinuva in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Single Sinuva MF Stent Users with no prior use of Propel or Sinuva	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
2019	201	14.3%
2020	545	38.9%
2021	*****	36.8%
2022	*****	*****
Health Characteristics		
Mean number of ambulatory encounters	13.7	9.9
Mean number of emergency room encounters	0.2	0.5
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.2	3.2
Mean number of filled prescriptions	17.7	13.8
Mean number of generics dispensed	8.6	5.0
Mean number of unique drug classes dispensed	8.0	4.5

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1b. Aggregated Characteristics of Sinuva Single MF Stent Users with no prior use of Propel or Sinuva, excluding Glaucoma, in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Sinuva Single MF Stent Users with no prior use of Propel or Sinuva, excluding Glaucoma	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Unique patients	1,295	N/A
Demographic Characteristics		
Age (years)	56.2	12.5
Age		
0-1 years	0	0.0%
2-4 years	0	0.0%
5-9 years	0	0.0%
10-14 years	*****	*****
15-18 years	*****	*****
19-21 years	*****	*****
22-44 years	304	23.5%
45-64 years	442	34.1%
65-74 years	381	29.4%
≥ 75 years	133	*****
Sex		
Female	513	39.6%
Male	782	60.4%
Race[2]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	668	51.6%
White	577	44.6%
Hispanic origin		
Yes	*****	*****
No	503	38.8%
Unknown	773	59.7%
Year		
2016	0	0.0%
2017	0	0.0%
2018	*****	*****

Table 1b. Aggregated Characteristics of Sinuva Single MF Stent Users with no prior use of Propel or Sinuva, excluding Glaucoma, in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Sinuva Single MF Stent Users with no prior use of Propel or Sinuva, excluding Glaucoma	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
2019	191	14.7%
2020	509	39.3%
2021	469	36.2%
2022	*****	*****
Health Characteristics		
Mean number of ambulatory encounters	13.4	9.8
Mean number of emergency room encounters	0.2	0.5
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.1	3.1
Mean number of filled prescriptions	17.4	13.4
Mean number of generics dispensed	8.5	4.9
Mean number of unique drug classes dispensed	7.9	4.4

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1c. Aggregated Characteristics of Single Sinuva MF Stent Users with no prior use of Propel or Sinuva, excluding Cataracts, in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Single Sinuva MF Stent Users with no prior use of Propel or Sinuva, excluding Cataracts	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Unique patients	1,261	N/A
Demographic Characteristics		
Age (years)	55.8	12.7
Age		
0-1 years	0	0.0%
2-4 years	0	0.0%
5-9 years	0	0.0%
10-14 years	*****	*****
15-18 years	*****	*****
19-21 years	*****	*****
22-44 years	306	24.3%
45-64 years	445	35.3%
65-74 years	340	27.0%
≥ 75 years	135	*****
Sex		
Female	502	39.8%
Male	759	60.2%
Race[2]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	670	53.1%
White	544	43.1%
Hispanic origin		
Yes	*****	*****
No	473	37.5%
Unknown	770	61.1%
Year		
2016	0	0.0%
2017	0	0.0%
2018	*****	*****

Table 1c. Aggregated Characteristics of Single Sinuva MF Stent Users with no prior use of Propel or Sinuva, excluding Cataracts, in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Single Sinuva MF Stent Users with no prior use of Propel or Sinuva, excluding Cataracts	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
2019	187	14.8%
2020	500	39.7%
2021	447	35.4%
2022	*****	*****
Health Characteristics		
Mean number of ambulatory encounters	13.3	9.7
Mean number of emergency room encounters	0.2	0.5
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.1	3.1
Mean number of filled prescriptions	17.6	14.1
Mean number of generics dispensed	8.5	5.0
Mean number of unique drug classes dispensed	7.9	4.5

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1d. Aggregated Characteristics of Single Sinuva MF Stent Users with no prior use of Sinuva in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Single Sinuva MF Stent Users	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Unique patients	1,500	N/A
Demographic Characteristics		
Age (years)	57.2	12.6
Age		
0-1 years	0	0.0%
2-4 years	0	0.0%
5-9 years	0	0.0%
10-14 years	*****	*****
15-18 years	*****	*****
19-21 years	*****	*****
22-44 years	333	22.2%
45-64 years	495	33.0%
65-74 years	457	30.5%
≥ 75 years	179	11.9%
Sex		
Female	600	40.0%
Male	900	60.0%
Race[2]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	750	50.0%
White	690	46.0%
Hispanic origin		
Yes	*****	*****
No	611	40.7%
Unknown	867	57.8%
Year		
2016	0	0.0%
2017	0	0.0%
2018	*****	*****
2019	218	14.5%
2020	578	38.5%

Table 1d. Aggregated Characteristics of Single Sinuva MF Stent Users with no prior use of Sinuva in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Single Sinuva MF Stent Users	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
2021	546	36.4%
2022	*****	*****
Health Characteristics		
Mean number of ambulatory encounters	14.0	10.0
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.3	3.6
Mean number of filled prescriptions	17.9	13.8
Mean number of generics dispensed	8.7	5.0
Mean number of unique drug classes dispensed	8.1	4.6

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1e. Aggregated Characteristics of Single Sinuva MF Stent Users with no prior use of Sinuva, excluding Glaucoma, in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Single Sinuva MF Stent Users, excluding Glaucoma	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Unique patients	1,387	N/A
Demographic Characteristics		
Age (years)	56.1	12.4
Age		
0-1 years	0	0.0%
2-4 years	0	0.0%
5-9 years	0	0.0%
10-14 years	*****	*****
15-18 years	*****	*****
19-21 years	*****	*****
22-44 years	331	23.9%
45-64 years	474	34.2%
65-74 years	407	29.3%
≥ 75 years	*****	*****
Sex		
Female	551	39.7%
Male	836	60.3%
Race[2]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	715	51.6%
White	615	44.3%
Hispanic origin		
Yes	*****	*****
No	535	38.6%
Unknown	831	59.9%
Year		
2016	0	0.0%
2017	0	0.0%
2018	*****	*****

Table 1e. Aggregated Characteristics of Single Sinuva MF Stent Users with no prior use of Sinuva, excluding Glaucoma, in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Single Sinuva MF Stent Users, excluding Glaucoma	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
2019	207	14.9%
2020	541	39.0%
2021	*****	35.8%
2022	*****	*****
Health Characteristics		
Mean number of ambulatory encounters	13.7	9.9
Mean number of emergency room encounters	0.2	0.5
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.2	3.5
Mean number of filled prescriptions	17.6	13.4
Mean number of generics dispensed	8.6	5.0
Mean number of unique drug classes dispensed	8.0	4.5

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1f. Aggregated Characteristics of Single Sinuva MF Stent Users with no prior use of Sinuva, excluding Cataracts, in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Single Sinuva MF Stent Users, excluding Cataracts	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Unique patients	1,349	N/A
Demographic Characteristics		
Age (years)	55.6	12.7
Age		
0-1 years	0	0.0%
2-4 years	0	0.0%
5-9 years	0	0.0%
10-14 years	*****	*****
15-18 years	*****	*****
19-21 years	*****	*****
22-44 years	333	24.7%
45-64 years	476	35.3%
65-74 years	362	26.8%
≥ 75 years	*****	*****
Sex		
Female	540	40.0%
Male	809	60.0%
Race[2]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	716	53.1%
White	579	42.9%
Hispanic origin		
Yes	*****	*****
No	502	37.2%
Unknown	827	61.3%
Year		
2016	0	0.0%
2017	0	0.0%
2018	*****	*****

Table 1f. Aggregated Characteristics of Single Sinuva MF Stent Users with no prior use of Sinuva, excluding Cataracts, in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Single Sinuva MF Stent Users, excluding Cataracts	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
2019	203	15.0%
2020	531	39.4%
2021	472	35.0%
2022	*****	*****
Health Characteristics		
Mean number of ambulatory encounters	13.5	9.9
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.2	3.6
Mean number of filled prescriptions	17.8	14.1
Mean number of generics dispensed	8.6	5.0
Mean number of unique drug classes dispensed	8.0	4.5

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1g. Aggregated Characteristics of Repeat Sinuva MF Stent Users in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Repeat Sinuva MF Stent Users	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Unique patients	1,526	N/A
Demographic Characteristics		
Age (years)	57.1	12.6
Age		
0-1 years	0	0.0%
2-4 years	0	0.0%
5-9 years	0	0.0%
10-14 years	*****	*****
15-18 years	*****	*****
19-21 years	*****	*****
22-44 years	342	22.4%
45-64 years	503	33.0%
65-74 years	464	30.4%
≥ 75 years	181	11.9%
Sex		
Female	610	40.0%
Male	916	60.0%
Race[2]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	40	2.6%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	769	50.4%
White	697	45.7%
Hispanic origin		
Yes	*****	*****
No	618	40.5%
Unknown	885	58.0%
Year		
2016	0	0.0%
2017	0	0.0%
2018	*****	*****

Table 1g. Aggregated Characteristics of Repeat Sinuva MF Stent Users in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Repeat Sinuva MF Stent Users	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
2019	220	14.4%
2020	591	38.7%
2021	554	36.3%
2022	*****	*****
Health Characteristics		
Mean number of ambulatory encounters	14.0	10.0
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	2.3	3.5
Mean number of filled prescriptions	17.9	13.8
Mean number of generics dispensed	8.7	5.0
Mean number of unique drug classes dispensed	8.1	4.5

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1h. Aggregated Characteristics of Single Propel MF Stent Users in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Single Propel MF Stent Users	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
Unique patients	35,774	N/A
Demographic Characteristics		
Age (years)	58.8	13.7
Age		
0-1 years	13	0.0%
2-4 years	*****	*****
5-9 years	*****	*****
10-14 years	*****	*****
15-18 years	*****	*****
19-21 years	*****	*****
22-44 years	6,464	18.1%
45-64 years	9,953	27.8%
65-74 years	11,482	32.1%
≥ 75 years	6,162	17.2%
Sex		
Female	15,258	42.7%
Male	20,516	57.3%
Race[2]		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	12,692	35.5%
White	20,160	56.4%
Hispanic origin		
Yes	*****	*****
No	20,785	58.1%
Unknown	13,592	38.0%
Year		
2016	5,114	14.3%
2017	6,345	17.7%
2018	7,044	19.7%

Table 1h. Aggregated Characteristics of Single Propel MF Stent Users in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Single Propel MF Stent Users	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[1]**
2019	5,916	16.5%
2020	4,764	13.3%
2021	5,618	15.7%
2022	*****	*****
Health Characteristics		
Mean number of ambulatory encounters	16.2	12.7
Mean number of emergency room encounters	0.4	1.3
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.6	8.5
Mean number of filled prescriptions	19.8	17.1
Mean number of generics dispensed	9.1	5.6
Mean number of unique drug classes dispensed	8.5	5.0

[1]Value represents standard deviation where no % follows the value.

[2]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2a. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

		Distribution of Days Supplied by Dispensing						
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva	1,637	1	1	1	1	90	6.9	14.2
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma	1,513	1	1	1	1	90	7.1	14.5
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts								
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts	1,477	1	1	1	1	90	7.2	14.5
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Single Sinuva MF Stent Users with no Prior use of Sinuva	1,764	1	1	1	1	90	7.1	14.6
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma								
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma	1,631	1	1	1	1	90	7.4	14.9
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts								
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts	1,589	1	1	1	1	90	7.5	14.9
Repeat Sinuva MF Stent Users								
Repeat Sinuva MF Stent Users	1,805	1	1	1	1	90	7.1	14.6
Single Propel MF Stent Users								
Single Propel MF Stent Users	61,721	1	1	1	1	1	1.0	0.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Sex

		Distribution of Days Supplied by Dispensing						
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Overall	*1,637*	*1*	*1*	*1*	*1*	*90*	*6.9*	*14.2*
Female	650	1	1	1	1	90	6.5	13.4
Male	987	1	1	1	1	90	7.1	14.7
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Overall	*1,513*	*1*	*1*	*1*	*1*	*90*	*7.1*	*14.5*
Female	598	1	1	1	1	90	6.9	13.8
Male	915	1	1	1	1	90	7.3	15.0
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts								
Overall	*1,477*	*1*	*1*	*1*	*1*	*90*	*7.2*	*14.5*
Female	587	1	1	1	1	90	6.8	13.4
Male	890	1	1	1	1	90	7.5	15.2
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Overall	*1,764*	*1*	*1*	*1*	*1*	*90*	*7.1*	*14.6*
Female	703	1	1	1	1	90	7.0	14.4
Male	1,061	1	1	1	1	90	7.1	14.7
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma								
Overall	*1,631*	*1*	*1*	*1*	*1*	*90*	*7.4*	*14.9*
Female	647	1	1	1	1	90	7.4	14.9
Male	984	1	1	1	1	90	7.3	15.0
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts								
Overall	*1,589*	*1*	*1*	*1*	*1*	*90*	*7.5*	*14.9*
Female	636	1	1	1	1	90	7.4	14.6
Male	953	1	1	1	1	90	7.5	15.2
Repeat Sinuva MF Stent Users								

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Sex

		Distribution of Days Supplied by Dispensing						
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Overall	*1,805*	*1*	*1*	*1*	*1*	*90*	*7.1*	*14.6*
Female	721	1	1	1	1	90	7.3	14.8
Male	1,084	1	1	1	1	90	7.0	14.5
Single Propel MF Stent Users								
Overall	*61,721*	*1*	*1*	*1*	*1*	*1*	*1.0*	*0.0*
Female	26,818	1	1	1	1	1	1.0	0.0
Male	34,903	1	1	1	1	1	1.0	0.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2c. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Overall	*1,637*	*1*	*1*	*1*	*1*	*90*	*6.9*	*14.2*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	2	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	1	30	3.6	8.7
19-21 years	26	1	1	1	1	30	7.7	12.5
22-44 years	366	1	1	1	30	90	10.7	17.4
45-64 years	545	1	1	1	30	90	10.0	15.4
65-74 years	501	1	1	1	1	90	2.5	9.9
≥ 75 years	186	1	1	1	1	90	1.8	7.2
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Overall	*1,513*	*1*	*1*	*1*	*1*	*90*	*7.1*	*14.5*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	2	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	1	30	3.6	8.7
19-21 years	26	1	1	1	1	30	7.7	12.5
22-44 years	364	1	1	1	30	90	10.8	17.5
45-64 years	518	1	1	1	30	90	10.0	15.5
65-74 years	442	1	1	1	1	90	2.6	10.3
≥ 75 years	150	1	1	1	1	90	2.0	8.0

Table 2c. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts								
Overall	*1,477*	*1*	*1*	*1*	*1*	*90*	*7.2*	*14.5*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	2	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	1	30	3.6	8.7
19-21 years	26	1	1	1	1	30	7.7	12.5
22-44 years	366	1	1	1	30	90	10.7	17.4
45-64 years	528	1	1	1	30	90	10.0	15.5
65-74 years	396	1	1	1	1	90	2.3	9.7
≥ 75 years	148	1	1	1	1	90	2.0	8.0
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Overall	*1,764*	*1*	*1*	*1*	*1*	*90*	*7.1*	*14.6*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	2	1	1	1	1	1	1.0	0.0
15-18 years	12	1	1	1	1	30	5.8	11.3
19-21 years	26	1	1	1	1	30	7.7	12.5
22-44 years	397	1	1	1	30	90	10.9	17.6
45-64 years	592	1	1	1	30	90	10.2	15.6
65-74 years	538	1	1	1	1	90	2.7	10.9
≥ 75 years	197	1	1	1	1	90	1.7	7.0

Table 2c. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma								
Overall	*1,631*	*1*	*1*	*1*	*1*	*90*	*7.4*	*14.9*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	2	1	1	1	1	1	1.0	0.0
15-18 years	12	1	1	1	1	30	5.8	11.3
19-21 years	26	1	1	1	1	30	7.7	12.5
22-44 years	395	1	1	1	30	90	11.0	17.6
45-64 years	562	1	1	1	30	90	10.2	15.7
65-74 years	477	1	1	1	1	90	2.8	11.5
≥ 75 years	157	1	1	1	1	90	1.9	7.8
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts								
Overall	*1,589*	*1*	*1*	*1*	*1*	*90*	*7.5*	*14.9*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	2	1	1	1	1	1	1.0	0.0
15-18 years	12	1	1	1	1	30	5.8	11.3
19-21 years	26	1	1	1	1	30	7.7	12.5
22-44 years	397	1	1	1	30	90	10.9	17.6
45-64 years	572	1	1	1	30	90	10.2	15.7
65-74 years	424	1	1	1	1	90	2.7	11.2
≥ 75 years	156	1	1	1	1	90	1.9	7.8

Table 2c. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Repeat Sinuva MF Stent Users								
Overall	*1,805*	*1*	*1*	*1*	*1*	*90*	*7.1*	*14.6*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	2	1	1	1	1	1	1.0	0.0
15-18 years	12	1	1	1	1	30	5.8	11.3
19-21 years	26	1	1	1	1	30	7.7	12.5
22-44 years	407	1	1	1	30	90	10.7	17.5
45-64 years	609	1	1	1	30	90	10.2	15.6
65-74 years	550	1	1	1	1	90	2.8	10.9
≥ 75 years	199	1	1	1	1	90	2.2	9.3
Single Propel MF Stent Users								
Overall	*61,721*	*1*	*1*	*1*	*1*	*1*	*1.0*	*0.0*
0-1 years	23	1	1	1	1	1	1.0	0.0
2-4 years	72	1	1	1	1	1	1.0	0.0
5-9 years	244	1	1	1	1	1	1.0	0.0
10-14 years	664	1	1	1	1	1	1.0	0.0
15-18 years	903	1	1	1	1	1	1.0	0.0
19-21 years	622	1	1	1	1	1	1.0	0.0
22-44 years	9,847	1	1	1	1	1	1.0	0.0
45-64 years	16,275	1	1	1	1	1	1.0	0.0
65-74 years	20,779	1	1	1	1	1	1.0	0.0
≥ 75 years	12,292	1	1	1	1	1	1.0	0.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 3a. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

		Distribution of Cumulative Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva	1,401	1	1	1	1	270	8.0	20.1
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma	1,295	1	1	1	2	270	8.3	20.5
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts								
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts	1,261	1	1	1	2	270	8.5	20.8
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Single Sinuva MF Stent Users with no Prior use of Sinuva	1,500	1	1	1	2	270	8.3	20.6
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma								
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma	1,387	1	1	1	2	270	8.6	20.9
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts								
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts	1,349	1	1	1	2	270	8.8	21.3
Repeat Sinuva MF Stent Users								
Repeat Sinuva MF Stent Users	1,526	1	1	1	2	270	8.4	20.8
Single Propel MF Stent Users								
Single Propel MF Stent Users	35,774	1	1	1	2	252	1.7	3.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Sex

		Distribution of Cumulative Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Overall	*1,401*	*1*	*1*	*1*	*1*	*270*	*8.0*	*20.1*
Female	560	1	1	1	1	270	7.6	19.4
Male	841	1	1	1	1	210	8.3	20.5
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Overall	*1,295*	*1*	*1*	*1*	*2*	*270*	*8.3*	*20.5*
Female	513	1	1	1	2	270	8.0	20.1
Male	782	1	1	1	2	210	8.5	20.7
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts								
Overall	*1,261*	*1*	*1*	*1*	*2*	*270*	*8.5*	*20.8*
Female	502	1	1	1	2	270	7.9	19.8
Male	759	1	1	1	1	210	8.8	21.4
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Overall	*1,500*	*1*	*1*	*1*	*2*	*270*	*8.3*	*20.6*
Female	600	1	1	1	2	270	8.3	20.9
Male	900	1	1	1	2	210	8.3	20.4
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma								
Overall	*1,387*	*1*	*1*	*1*	*2*	*270*	*8.6*	*20.9*
Female	551	1	1	1	2	270	8.7	21.5
Male	836	1	1	1	2	210	8.6	20.6
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts								
Overall	*1,349*	*1*	*1*	*1*	*2*	*270*	*8.8*	*21.3*
Female	540	1	1	1	2	270	8.7	21.4

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Sex

		Distribution of Cumulative Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	809	1	1	1	2	210	8.9	21.2
Repeat Sinuva MF Stent Users								
Overall	*1,526*	*1*	*1*	*1*	*2*	*270*	*8.4*	*20.8*
Female	610	1	1	1	2	270	8.6	21.8
Male	916	1	1	1	2	210	8.3	20.2
Single Propel MF Stent Users								
Overall	*35,774*	*1*	*1*	*1*	*2*	*252*	*1.7*	*3.7*
Female	15,258	1	1	1	2	210	1.8	3.6
Male	20,516	1	1	1	1	252	1.7	3.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3c. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of Cumulative Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Overall	*1,401*	*1*	*1*	*1*	*1*	*270*	*8.0*	*20.1*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	*****	1	1	1	1	1	1.0	0.0
15-18 years	*****	1	1	1	1	30	4.0	9.1
19-21 years	23	1	1	1	2	61	8.7	16.0
22-44 years	306	1	1	1	30	270	12.8	26.5
45-64 years	462	1	1	1	30	210	11.8	22.6
65-74 years	429	1	1	1	1	181	2.9	12.5
≥ 75 years	169	1	1	1	1	90	2.0	7.5
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Overall	*1,295*	*1*	*1*	*1*	*2*	*270*	*8.3*	*20.5*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	*****	1	1	1	1	1	1.0	0.0
15-18 years	*****	1	1	1	1	30	4.0	9.1
19-21 years	23	1	1	1	2	61	8.7	16.0
22-44 years	304	1	1	1	30	270	12.9	26.6
45-64 years	442	1	1	1	30	210	11.7	22.3
65-74 years	381	1	1	1	1	181	3.0	13.1

Table 3c. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of Cumulative Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 75 years	133	1	1	1	1	90	2.2	8.5
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts								
Overall	*1,261*	*1*	*1*	*1*	*2*	*270*	*8.5*	*20.8*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	*****	1	1	1	1	1	1.0	0.0
15-18 years	*****	1	1	1	1	30	4.0	9.1
19-21 years	23	1	1	1	2	61	8.7	16.0
22-44 years	306	1	1	1	30	270	12.8	26.5
45-64 years	445	1	1	1	30	210	11.9	22.9
65-74 years	340	1	1	1	1	181	2.7	12.6
≥ 75 years	135	1	1	1	1	90	2.2	8.4
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Overall	*1,500*	*1*	*1*	*1*	*2*	*270*	*8.3*	*20.6*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	*****	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	2	30	6.4	11.7
19-21 years	23	1	1	1	2	61	8.7	16.0
22-44 years	333	1	1	1	30	270	13.0	26.1
45-64 years	495	1	1	1	30	210	12.2	22.8

Table 3c. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of Cumulative Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
65-74 years	457	1	1	1	1	181	3.2	14.7
≥ 75 years	179	1	1	1	1	90	1.9	7.3
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma								
Overall	*1,387*	*1*	*1*	*1*	*2*	*270*	*8.6*	*20.9*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	*****	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	2	30	6.4	11.7
19-21 years	23	1	1	1	2	61	8.7	16.0
22-44 years	331	1	1	1	30	270	13.1	26.2
45-64 years	474	1	1	1	30	210	12.1	22.5
65-74 years	407	1	1	1	1	181	3.3	15.4
≥ 75 years	139	1	1	1	1	90	2.2	8.3
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts								
Overall	*1,349*	*1*	*1*	*1*	*2*	*270*	*8.8*	*21.3*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	*****	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	2	30	6.4	11.7
19-21 years	23	1	1	1	2	61	8.7	16.0
22-44 years	333	1	1	1	30	270	13.0	26.1

Table 3c. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of Cumulative Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
45-64 years	476	1	1	1	30	210	12.2	23.1
65-74 years	362	1	1	1	1	181	3.1	15.4
≥ 75 years	142	1	1	1	1	90	2.1	8.2
Repeat Sinuva MF Stent Users								
Overall	*1,526*	*1*	*1*	*1*	*2*	*270*	*8.4*	*20.8*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	*****	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	2	30	6.4	11.7
19-21 years	23	1	1	1	2	61	8.7	16.0
22-44 years	342	1	1	1	30	270	12.7	25.9
45-64 years	503	1	1	1	30	210	12.4	23.5
65-74 years	464	1	1	1	1	181	3.3	14.6
≥ 75 years	181	1	1	1	1	90	2.4	9.8
Single Propel MF Stent Users								
Overall	*35,774*	*1*	*1*	*1*	*2*	*252*	*1.7*	*3.7*
0-1 years	13	1	1	2	2	4	1.8	0.9
2-4 years	46	1	1	1	2	6	1.6	1.0
5-9 years	166	1	1	1	2	9	1.5	1.1
10-14 years	424	1	1	1	1	106	1.6	5.1
15-18 years	633	1	1	1	1	35	1.4	1.6
19-21 years	431	1	1	1	1	22	1.4	1.6

Table 3c. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of Cumulative Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
22-44 years	6,464	1	1	1	1	252	1.5	3.7
45-64 years	9,953	1	1	1	1	96	1.6	2.5
65-74 years	11,482	1	1	1	2	149	1.8	3.4
≥ 75 years	6,162	1	1	1	2	210	2.0	5.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 4a. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

		Distribution of Treatment Episode Durations, days						
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva	1,626	1	1	1	1	120	6.9	14.5
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma	1,503	1	1	1	1	120	7.2	14.8
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts								
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts	1,466	1	1	1	1	120	7.3	14.8
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Single Sinuva MF Stent Users with no Prior use of Sinuva	1,750	1	1	1	1	180	7.1	15.2
Single Sinuva MF Stent Users with no Prior use of Sinuva, Excluding Glaucoma								
Single Sinuva MF Stent Users with no Prior use of Sinuva, Excluding Glaucoma	1,619	1	1	1	1	180	7.4	15.6
Single Sinuva MF Stent Users with no Prior use of Sinuva, Excluding Cataracts								
Single Sinuva MF Stent Users with no Prior use of Sinuva, Excluding Cataracts	1,576	1	1	1	1	180	7.5	15.6
Repeat Sinuva MF Stent Users								
Repeat Sinuva MF Stent Users	1,791	1	1	1	1	180	7.1	15.2
Single Propel MF Stent Users								
Single Propel MF Stent Users	59,447	1	1	1	1	112	1.0	0.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Sex

		Distribution of Treatment Episode Durations, days						
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Overall	*1,626*	*1*	*1*	*1*	*1*	*120*	*6.9*	*14.5*
Female	645	1	1	1	1	90	6.6	13.6
Male	981	1	1	1	1	120	7.1	15.0
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Overall	*1,503*	*1*	*1*	*1*	*1*	*120*	*7.2*	*14.8*
Female	593	1	1	1	1	90	6.9	14.0
Male	910	1	1	1	1	120	7.3	15.3
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts								
Overall	*1,466*	*1*	*1*	*1*	*1*	*120*	*7.3*	*14.8*
Female	582	1	1	1	1	90	6.8	13.7
Male	884	1	1	1	1	120	7.6	15.6
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Overall	*1,750*	*1*	*1*	*1*	*1*	*180*	*7.1*	*15.2*
Female	696	1	1	1	1	180	7.1	15.4
Male	1,054	1	1	1	1	120	7.1	15.0
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma								
Overall	*1,619*	*1*	*1*	*1*	*1*	*180*	*7.4*	*15.6*
Female	641	1	1	1	1	180	7.5	15.9
Male	978	1	1	1	1	120	7.3	15.4
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts								
Overall	*1,576*	*1*	*1*	*1*	*1*	*180*	*7.5*	*15.6*
Female	630	1	1	1	1	180	7.4	15.6
Male	946	1	1	1	1	120	7.6	15.6

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Sex

		Distribution of Treatment Episode Durations, days						
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Repeat Sinuva MF Stent Users								
Overall	*1,791*	*1*	*1*	*1*	*1*	*180*	*7.1*	*15.2*
Female	714	1	1	1	1	180	7.3	15.7
Male	1,077	1	1	1	1	120	7.0	14.9
Single Propel MF Stent Users								
Overall	*59,447*	*1*	*1*	*1*	*1*	*112*	*1.0*	*0.8*
Female	26,011	1	1	1	1	29	1.0	0.4
Male	33,436	1	1	1	1	112	1.0	1.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4c. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of Treatment Episode Durations, days						
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Overall	*1,626*	*1*	*1*	*1*	*1*	*120*	*6.9*	*14.5*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	2	1	1	1	1	1	1.0	0.0
15-18 years	10	1	1	1	1	30	4.0	9.1
19-21 years	26	1	1	1	1	30	7.7	12.5
22-44 years	359	1	1	1	30	120	10.9	18.3
45-64 years	542	1	1	1	30	90	10.1	15.6
65-74 years	501	1	1	1	1	90	2.5	9.9
≥ 75 years	186	1	1	1	1	90	1.8	7.2
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Overall	*1,503*	*1*	*1*	*1*	*1*	*120*	*7.2*	*14.8*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	2	1	1	1	1	1	1.0	0.0
15-18 years	10	1	1	1	1	30	4.0	9.1
19-21 years	26	1	1	1	1	30	7.7	12.5
22-44 years	357	1	1	1	30	120	11.0	18.4
45-64 years	516	1	1	1	30	90	10.0	15.7
65-74 years	442	1	1	1	1	90	2.6	10.3
≥ 75 years	150	1	1	1	1	90	2.0	8.0

Table 4c. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts								
Overall	*1,466*	*1*	*1*	*1*	*1*	*120*	*7.3*	*14.8*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	2	1	1	1	1	1	1.0	0.0
15-18 years	10	1	1	1	1	30	4.0	9.1
19-21 years	26	1	1	1	1	30	7.7	12.5
22-44 years	359	1	1	1	30	120	10.9	18.3
45-64 years	525	1	1	1	30	90	10.1	15.6
65-74 years	396	1	1	1	1	90	2.3	9.7
≥ 75 years	148	1	1	1	1	90	2.0	8.0
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Overall	*1,750*	*1*	*1*	*1*	*1*	*180*	*7.1*	*15.2*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	2	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	2	30	6.4	11.7
19-21 years	26	1	1	1	1	30	7.7	12.5
22-44 years	390	1	1	1	30	120	11.1	18.4
45-64 years	587	1	1	1	30	90	10.3	15.9
65-74 years	537	1	1	1	1	180	2.7	12.2
≥ 75 years	197	1	1	1	1	90	1.7	7.0

Table 4c. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma								
Overall	*1,619*	*1*	*1*	*1*	*1*	*180*	*7.4*	*15.6*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	2	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	2	30	6.4	11.7
19-21 years	26	1	1	1	1	30	7.7	12.5
22-44 years	388	1	1	1	30	120	11.2	18.4
45-64 years	559	1	1	1	30	90	10.2	16.0
65-74 years	476	1	1	1	1	180	2.8	12.9
≥ 75 years	157	1	1	1	1	90	1.9	7.8
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts								
Overall	*1,576*	*1*	*1*	*1*	*1*	*180*	*7.5*	*15.6*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	2	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	2	30	6.4	11.7
19-21 years	26	1	1	1	1	30	7.7	12.5
22-44 years	390	1	1	1	30	120	11.1	18.4
45-64 years	568	1	1	1	30	90	10.2	15.9
65-74 years	423	1	1	1	1	180	2.7	12.8
≥ 75 years	156	1	1	1	1	90	1.9	7.8

Table 4c. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of Treatment Episode Durations, days						
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Repeat Sinuva MF Stent Users								
Overall	*1,791*	*1*	*1*	*1*	*1*	*180*	*7.1*	*15.2*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	2	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	2	30	6.4	11.7
19-21 years	26	1	1	1	1	30	7.7	12.5
22-44 years	400	1	1	1	30	120	10.9	18.2
45-64 years	604	1	1	1	30	90	10.3	15.8
65-74 years	549	1	1	1	1	180	2.8	12.2
≥ 75 years	199	1	1	1	1	90	2.2	9.3
Single Propel MF Stent Users								
Overall	*59,447*	*1*	*1*	*1*	*1*	*112*	*1.0*	*0.8*
0-1 years	23	1	1	1	1	1	1.0	0.0
2-4 years	66	1	1	1	1	3	1.1	0.3
5-9 years	229	1	1	1	1	5	1.1	0.4
10-14 years	549	1	1	1	1	45	1.2	2.5
15-18 years	877	1	1	1	1	5	1.0	0.2
19-21 years	604	1	1	1	1	10	1.0	0.4
22-44 years	9,360	1	1	1	1	112	1.1	1.6
45-64 years	15,769	1	1	1	1	27	1.0	0.4
65-74 years	20,240	1	1	1	1	34	1.0	0.4
≥ 75 years	11,730	1	1	1	1	28	1.0	0.5

NaN: Not a number

Table 5a. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

		Distribution of First Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva	1,401	1	1	1	1	90	6.5	14.3
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma	1,295	1	1	1	1	90	6.8	14.7
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts								
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts	1,261	1	1	1	1	90	6.9	14.6
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Single Sinuva MF Stent Users with no Prior use of Sinuva	1,500	1	1	1	1	180	6.9	15.2
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma								
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma	1,387	1	1	1	1	180	7.2	15.6
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts								
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts	1,349	1	1	1	1	180	7.2	15.6
Repeat Sinuva MF Stent Users								
Repeat Sinuva MF Stent Users	1,526	1	1	1	1	180	6.9	15.2
Single Propel MF Stent Users								
Single Propel MF Stent Users	35,774	1	1	1	1	34	1.0	0.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Sex

		Distribution of First Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Overall	*1,401*	*1*	*1*	*1*	*1*	*90*	*6.5*	*14.3*
Female	560	1	1	1	1	90	6.6	13.9
Male	841	1	1	1	1	90	6.5	14.5
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Overall	*1,295*	*1*	*1*	*1*	*1*	*90*	*6.8*	*14.7*
Female	513	1	1	1	1	90	7.0	14.4
Male	782	1	1	1	1	90	6.8	14.8
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts								
Overall	*1,261*	*1*	*1*	*1*	*1*	*90*	*6.9*	*14.6*
Female	502	1	1	1	1	90	6.9	14.0
Male	759	1	1	1	1	90	6.9	15.0
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Overall	*1,500*	*1*	*1*	*1*	*1*	*180*	*6.9*	*15.2*
Female	600	1	1	1	1	180	7.2	16.0
Male	900	1	1	1	1	90	6.6	14.6
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma								
Overall	*1,387*	*1*	*1*	*1*	*1*	*180*	*7.2*	*15.6*
Female	551	1	1	1	1	180	7.7	16.5
Male	836	1	1	1	1	90	6.9	15.0
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts								
Overall	*1,349*	*1*	*1*	*1*	*1*	*180*	*7.2*	*15.6*
Female	540	1	1	1	1	180	7.6	16.2
Male	809	1	1	1	1	90	7.0	15.2

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Sex

		Distribution of First Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Repeat Sinuva MF Stent Users								
Overall	*1,526*	*1*	*1*	*1*	*1*	*180*	*6.9*	*15.2*
Female	610	1	1	1	1	180	7.4	16.2
Male	916	1	1	1	1	90	6.6	14.5
Single Propel MF Stent Users								
Overall	*35,774*	*1*	*1*	*1*	*1*	*34*	*1.0*	*0.4*
Female	15,258	1	1	1	1	29	1.0	0.4
Male	20,516	1	1	1	1	34	1.0	0.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5c. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of First Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Overall	*1,401*	*1*	*1*	*1*	*1*	*90*	*6.5*	*14.3*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	*****	1	1	1	1	1	1.0	0.0
15-18 years	*****	1	1	1	1	30	4.0	9.1
19-21 years	23	1	1	1	1	30	7.3	12.2
22-44 years	306	1	1	1	30	90	10.4	17.9
45-64 years	462	1	1	1	30	90	9.5	15.7
65-74 years	429	1	1	1	1	90	2.5	9.7
≥ 75 years	169	1	1	1	1	90	1.9	7.5
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Overall	*1,295*	*1*	*1*	*1*	*1*	*90*	*6.8*	*14.7*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	*****	1	1	1	1	1	1.0	0.0
15-18 years	*****	1	1	1	1	30	4.0	9.1
19-21 years	23	1	1	1	1	30	7.3	12.2
22-44 years	304	1	1	1	30	90	10.4	17.9
45-64 years	442	1	1	1	30	90	9.6	15.8
65-74 years	381	1	1	1	1	90	2.5	10.1

Table 5c. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of First Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 75 years	133	1	1	1	1	90	2.1	8.5
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts								
Overall	*1,261*	*1*	*1*	*1*	*1*	*90*	*6.9*	*14.6*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	*****	1	1	1	1	1	1.0	0.0
15-18 years	*****	1	1	1	1	30	4.0	9.1
19-21 years	23	1	1	1	1	30	7.3	12.2
22-44 years	306	1	1	1	30	90	10.4	17.9
45-64 years	445	1	1	1	30	90	9.5	15.8
65-74 years	340	1	1	1	1	90	2.3	9.3
≥ 75 years	135	1	1	1	1	90	2.1	8.4
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Overall	*1,500*	*1*	*1*	*1*	*1*	*180*	*6.9*	*15.2*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	*****	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	2	30	6.4	11.7
19-21 years	23	1	1	1	1	30	7.3	12.2
22-44 years	333	1	1	1	30	90	10.7	18.1
45-64 years	495	1	1	1	30	90	9.9	16.2

Table 5c. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of First Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
65-74 years	457	1	1	1	1	180	2.8	12.6
≥ 75 years	179	1	1	1	1	90	1.8	7.3
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma								
Overall	*1,387*	*1*	*1*	*1*	*1*	*180*	*7.2*	*15.6*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	*****	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	2	30	6.4	11.7
19-21 years	23	1	1	1	1	30	7.3	12.2
22-44 years	331	1	1	1	30	90	10.7	18.1
45-64 years	474	1	1	1	30	90	10.0	16.3
65-74 years	407	1	1	1	1	180	2.9	13.1
≥ 75 years	139	1	1	1	1	90	2.1	8.3
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts								
Overall	*1,349*	*1*	*1*	*1*	*1*	*180*	*7.2*	*15.6*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	*****	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	2	30	6.4	11.7
19-21 years	23	1	1	1	1	30	7.3	12.2
22-44 years	333	1	1	1	30	90	10.7	18.1

Table 5c. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of First Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
45-64 years	476	1	1	1	30	90	9.8	16.2
65-74 years	362	1	1	1	1	180	2.7	13.0
≥ 75 years	142	1	1	1	1	90	2.0	8.2
Repeat Sinuva MF Stent Users								
Overall	*1,526*	*1*	*1*	*1*	*1*	*180*	*6.9*	*15.2*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	*****	1	1	1	1	1	1.0	0.0
15-18 years	11	1	1	1	2	30	6.4	11.7
19-21 years	23	1	1	1	1	30	7.3	12.2
22-44 years	342	1	1	1	30	90	10.4	17.9
45-64 years	503	1	1	1	30	90	9.9	16.1
65-74 years	464	1	1	1	1	180	2.8	12.5
≥ 75 years	181	1	1	1	1	90	2.3	9.8
Single Propel MF Stent Users								
Overall	*35,774*	*1*	*1*	*1*	*1*	*34*	*1.0*	*0.4*
0-1 years	13	1	1	1	1	1	1.0	0.0
2-4 years	46	1	1	1	1	2	1.1	0.3
5-9 years	166	1	1	1	1	3	1.0	0.2
10-14 years	424	1	1	1	1	3	1.0	0.2
15-18 years	633	1	1	1	1	3	1.0	0.1
19-21 years	431	1	1	1	1	4	1.0	0.2

Table 5c. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of First Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
22-44 years	6,464	1	1	1	1	14	1.0	0.2
45-64 years	9,953	1	1	1	1	27	1.0	0.4
65-74 years	11,482	1	1	1	1	34	1.0	0.5
≥ 75 years	6,162	1	1	1	1	28	1.0	0.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 6a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

		Distribution of Treatment Episode Gap Durations, days						
	Total Number of Gaps[1]	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva	225	3	61	104	186	679	146.6	136.0
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Single Sinuva MF Stent Users with no Prior use of Propel or	208	3	58	105	186	653	144.7	131.8
Single Sinuva MF Stent Users with no Prior use of Propel Excluding Cataracts								
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts	205	3	60	103	182	679	142.4	135.2
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Single Sinuva MF Stent Users with no Prior use of Sinuva	250	3	62	106	186	1,048	150.7	149.2
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma								
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma	232	3	61	106	185	696	145.5	134.6
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts								
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts	227	3	60	104	182	1,048	148.0	150.6
Repeat Sinuva MF Stent Users								
Repeat Sinuva MF Stent Users	265	3	62	106	184	1,048	148.6	145.8
Single Propel MF Stent Users								
Single Propel MF Stent Users	23,673	1	13	48	207	2,269	182.4	306.1

[1]A single member with the exposure of interest could have more than one treatment episode, and therefore, more than one gap between episodes

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Sex

		Distribution of Treatment Episode Gap Durations, days						
	Total Number of Gaps[1]	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Overall	*225*	*3*	*61*	*104*	*186*	*679*	*146.6*	*136.0*
Female	85	3	62	102	186	608	136.6	117.3
Male	140	3	61	106	186	679	152.7	146.2
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Overall	*208*	*3*	*58*	*105*	*186*	*653*	*144.7*	*131.8*
Female	80	3	54	104	187	608	137.9	118.9
Male	128	3	61	106	185	653	149.0	139.5
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts								
Overall	*205*	*3*	*60*	*103*	*182*	*679*	*142.4*	*135.2*
Female	80	3	59	101	170	608	131.4	116.1
Male	125	3	60	104	184	679	149.4	146.2
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Overall	*250*	*3*	*62*	*106*	*186*	*1,048*	*150.7*	*149.2*
Female	96	3	62	104	197	1,048	153.4	160.7
Male	154	3	61	106	184	679	149.1	142.0
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma								
Overall	*232*	*3*	*61*	*106*	*185*	*696*	*145.5*	*134.6*
Female	90	3	56	104	188	696	145.6	134.3
Male	142	3	61	106	182	653	145.4	135.2
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts								
Overall	*227*	*3*	*60*	*104*	*182*	*1,048*	*148.0*	*150.6*
Female	90	3	62	103	182	1,048	150.6	163.2

Table 6b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Sex

		Distribution of Treatment Episode Gap Durations, days						
	Total Number of Gaps[1]	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	137	3	60	106	182	679	146.3	142.3
Repeat Sinuva MF Stent Users								
Overall	*265*	*3*	*62*	*106*	*184*	*1,048*	*148.6*	*145.8*
Female	104	3	64	105	197	1,048	152.5	155.0
Male	161	3	61	106	181	679	146.1	139.9
Single Propel MF Stent Users								
Overall	*23,673*	*1*	*13*	*48*	*207*	*2,269*	*182.4*	*306.1*
Female	10,753	1	13	49	207	2,267	180.4	299.8
Male	12,920	1	13	44	207	2,269	184.0	311.3

[1]A single member with the exposure of interest could have more than one treatment episode, and therefore, more than one gap between episodes
*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of Treatment Episode Gap Durations, days						
	Total Number of Gaps[1]	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva								
Overall	*225*	*3*	*61*	*104*	*186*	*679*	*146.6*	*136.0*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
15-18 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
19-21 years	3	117	117	304	640	640	353.7	265.0
22-44 years	53	5	28	61	103	312	84.0	75.6
45-64 years	80	3	44	109	186	679	152.2	152.5
65-74 years	72	6	93	114	250	653	172.8	131.7
≥ 75 years	17	3	102	172	205	490	168.1	122.6
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma								
Overall	*208*	*3*	*58*	*105*	*186*	*653*	*144.7*	*131.8*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
15-18 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
19-21 years	*3*	117	117	304	640	640	353.7	265.0
22-44 years	53	5	28	61	103	312	84.0	75.6
45-64 years	74	3	47	112	186	628	151.9	143.4
65-74 years	61	6	94	116	236	653	171.9	131.0
≥ 75 years	17	3	102	172	205	490	168.1	122.6

Table 6c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of Treatment Episode Gap Durations, days						
	Total Number of Gaps[1]	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts								
Overall	*205*	*3*	*60*	*103*	*182*	*679*	*142.4*	*135.2*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
15-18 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
19-21 years	*3*	117	117	304	640	640	353.7	265.0
22-44 years	53	5	28	61	103	312	84.0	75.6
45-64 years	80	3	44	109	186	679	152.2	152.5
65-74 years	56	6	90	110	173	653	163.5	126.6
≥ 75 years	13	3	102	172	216	490	179.9	132.1
Single Sinuva MF Stent Users with no Prior use of Sinuva								
Overall	*250*	*3*	*62*	*106*	*186*	*1,048*	*150.7*	*149.2*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
15-18 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
19-21 years	*3*	117	117	304	640	640	353.7	265.0
22-44 years	57	5	28	72	109	489	90.7	91.1
45-64 years	92	3	38	110	203	1,048	158.8	174.5
65-74 years	80	6	93	111	240	696	173.1	139.7
≥ 75 years	18	3	102	150	205	490	165.8	119.4
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma								

Table 6c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of Treatment Episode Gap Durations, days						
	Total Number of Gaps[1]	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Overall	*232*	*3*	*61*	*106*	*185*	*696*	*145.5*	*134.6*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
15-18 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
19-21 years	*3*	117	117	304	640	640	353.7	265.0
22-44 years	57	5	28	72	109	489	90.7	91.1
45-64 years	85	3	40	111	186	628	148.6	139.5
65-74 years	69	6	94	111	188	696	172.4	140.4
≥ 75 years	18	3	102	150	205	490	165.8	119.4
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts								
Overall	*227*	*3*	*60*	*104*	*182*	*1,048*	*148.0*	*150.6*
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
15-18 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
19-21 years	*3*	117	117	304	640	640	353.7	265.0
22-44 years	57	5	28	72	109	489	90.7	91.1
45-64 years	92	3	38	110	203	1,048	158.8	174.5
65-74 years	61	6	92	110	158	696	168.6	140.0
≥ 75 years	14	3	102	149	216	490	176.1	127.7
Repeat Sinuva MF Stent Users								
Overall	*265*	*3*	*62*	*106*	*184*	*1,048*	*148.6*	*145.8*

Table 6c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022, by Age Group

		Distribution of Treatment Episode Gap Durations, days						
	Total Number of Gaps[1]	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-1 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
2-4 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
5-9 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
10-14 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
15-18 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
19-21 years	*3*	117	117	304	640	640	353.7	265.0
22-44 years	58	5	28	72	109	489	90.8	90.3
45-64 years	101	3	47	110	186	1,048	155.8	167.8
65-74 years	85	6	92	111	188	696	168.7	137.2
≥ 75 years	18	3	102	150	205	490	165.8	119.4
Single Propel MF Stent Users								
Overall	*23,673*	*1*	*13*	*48*	*207*	*2,269*	*182.4*	*306.1*
0-1 years	10	12	34	214	351	1,029	271.0	307.1
2-4 years	20	9	95	179	237	550	191.4	128.4
5-9 years	63	1	40	103	295	1,261	211.6	270.5
10-14 years	125	1	57	133	304	1,726	223.8	263.8
15-18 years	244	1	16	86	234	2,058	169.2	245.0
19-21 years	173	1	21	81	167	1,406	153.3	213.7
22-44 years	2,896	1	19	72	233	2,147	184.3	275.5
45-64 years	5,816	1	13	55	214	2,149	181.0	289.7
65-74 years	8,758	1	13	42	216	2,269	197.6	336.8
≥ 75 years	5,568	1	6	31	160	2,267	158.8	292.2

[1]A single member with the exposure of interest could have more than one treatment episode, and therefore, more than one gap between episodes

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 7. Summary of Reasons First Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

		Censoring Reason											
		End of Exposure Episode[2]		Occurrence of User-Defined Censoring Criteria[3]		Evidence of Death[4]		Disenrollment[5]		End of Data[6]		End of Study Period[7]	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva													
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva	1,401	1,401	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma													
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma	1,295	1,295	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts													
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts	1,261	1,261	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Single Sinuva MF Stent Users with no Prior use of Sinuva													
Single Sinuva MF Stent Users with no Prior use of Sinuva	1,500	1,500	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma													
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma	1,387	1,387	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts													
Stent Users with no Prior use of Sinuva Excluding Cataracts	1,349	1,349	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%

Table 7. Summary of Reasons First Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

		Censoring Reason											
		End of Exposure Episode[2]		Occurrence of User-Defined Censoring Criteria[3]		Evidence of Death[4]		Disenrollment[5]		End of Data[6]		End of Study Period[7]	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Repeat Sinuva MF Stent Users													
Stent Users	1,526	1,526	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Single Propel MF Stent Users													
Single Propel MF Stent Users	35,774	35,774	100.0%	0	0.0%	24	*****	31	*****	0	0.0%	0	0.0%

[1]A patient's episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of patients.

[2]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

[3]Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

[4]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

[5]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

[6]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

[7]Represents episodes censored due to user-specified study end date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 8. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

		Censoring Reason											
		End of Exposure Episode[2]		Occurrence of User-Defined Censoring Criteria[3]		Evidence of Death[4]		Disenrollment[5]		End of Data[6]		End of Study Period[7]	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva													
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva	1,626	1,626	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma													
Users with no Prior use of Propel or Sinuva Excluding Glaucoma	1,503	1,503	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts													
Users with no Prior use of Propel or Sinuva Excluding Cataracts	1,466	1,466	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Single Sinuva MF Stent Users with no Prior use of Sinuva													
Stent Users with no Prior use of Sinuva	1,750	1,750	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma													
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma	1,619	1,619	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%

Table 8. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

		Censoring Reason											
		End of Exposure Episode[2]		Occurrence of User-Defined Censoring Criteria[3]		Evidence of Death[4]		Disenrollment[5]		End of Data[6]		End of Study Period[7]	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts													
Stent Users with no Prior use of Sinuva Excluding Cataracts	1,576	1,576	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Repeat Sinuva MF Stent Users													
Repeat Sinuva MF Stent Users	1,791	1,791	100.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
Single Propel MF Stent Users													
Users	59,447	59,447	100.0%	0	0.0%	34	*****	68	*****	0	0.0%	0	0.0%

[1]An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

[2]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

[3]Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

[4]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

[5]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

[6]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

[7]Represents episodes censored due to user-specified study end date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 9. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva		Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma		Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts		Single Sinuva MF Stent Users with no Prior use of Sinuva
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining
Members meeting enrollment and demographic requirements							
Enrolled at any point during the query period	322,370,583	N/A	322,370,583	N/A	322,370,583	N/A	322,370,583
Had required coverage type (medical and/or drug coverage)	237,106,400	85,264,183	237,106,400	85,264,183	237,106,400	85,264,183	237,106,400
Enrolled during specified age range	237,104,917	1,483	237,104,917	1,483	237,104,917	1,483	237,104,917
Had requestable medical charts	237,104,917	0	237,104,917	0	237,104,917	0	237,104,917
Met demographic requirements (sex, race, and Hispanic origin)	237,089,841	15,076	237,089,841	15,076	237,089,841	15,076	237,089,841
Members with a valid index event							
Had any cohort-defining claim during the query period	3,248	237,086,593	3,248	237,086,593	3,248	237,086,593	3,248
Claim recorded during specified age range	3,248	0	3,248	0	3,248	0	3,248
Episode defining index claim recorded during the query period	3,248	0	3,248	0	3,248	0	3,248
Members with required pre-index history							
Had sufficient pre-index continuous enrollment	2,962	286	2,962	286	2,962	286	2,962
Met inclusion and exclusion criteria[1]	1,401	1,561	1,295	1,667	1,261	1,701	1,500
Evidence of cataract	N/A	N/A	N/A	N/A	N/A	295	N/A
Evidence of glaucoma	N/A	N/A	N/A	211	N/A	N/A	N/A
Evidence of propel	N/A	N/A	N/A	165	N/A	166	N/A

Table 9. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva		Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Glaucoma		Single Sinuva MF Stent Users with no Prior use of Propel or Sinuva Excluding Cataracts		Single Sinuva MF Stent Users with no Prior use of Sinuva
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining
Evidence of propel use	N/A	165	N/A	N/A	N/A	N/A	N/A
Evidence of sinuva	N/A	N/A	N/A	N/A	N/A	N/A	N/A
No evidence of nasal polyps	N/A	1,465	N/A	1,467	N/A	1,466	N/A
Members with required post-index follow-up							
Had sufficient post-index continuous enrollment	1,401	0	1,295	0	1,261	0	1,500
Final cohort							
Number of members	1,401	N/A	1,295	N/A	1,261	N/A	1,500

Table 9. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Sinuva MF Stent Users with no Prior use of Sinuva	Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma		Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts		Repeat Sinuva MF Stent Users		Single Propel MF Stent Users	
	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements									
Enrolled at any point during the query period	N/A	322,370,583	N/A	322,370,583	N/A	322,370,583	N/A	322,370,583	N/A
Had required coverage type (medical and/or drug coverage)	85,264,183	237,106,400	85,264,183	237,106,400	85,264,183	237,106,400	85,264,183	237,106,400	85,264,183
Enrolled during specified age range	1,483	237,104,917	1,483	237,104,917	1,483	237,104,917	1,483	237,104,917	1,483
Had requestable medical charts	0	237,104,917	0	237,104,917	0	237,104,917	0	237,104,917	0
Met demographic requirements (sex, race, and Hispanic origin)	15,076	237,089,841	15,076	237,089,841	15,076	237,089,841	15,076	237,089,841	15,076
Members with a valid index event									
Had any cohort-defining claim during the query period	237,086,593	3,248	237,086,593	3,248	237,086,593	3,248	237,086,593	11,654,019	225,435,822
Claim recorded during specified age range	0	3,248	0	3,248	0	3,248	0	11,653,971	48
Episode defining index claim recorded during the query period	0	3,248	0	3,248	0	3,248	0	11,592,553	61,418
Members with required pre-index history									
Had sufficient pre-index continuous enrollment	286	2,962	286	2,962	286	2,970	278	10,045,795	1,546,758
Met inclusion and exclusion criteria[1]	1,462	1,387	1,575	1,349	1,613	1,526	1,444	35,774	10,010,021
Evidence of cataract	N/A	N/A	N/A	N/A	294	N/A	N/A	N/A	N/A
Evidence of glaucoma	N/A	N/A	210	N/A	N/A	N/A	N/A	N/A	N/A
Evidence of propel	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Table 9. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2016 to July 31, 2022

	Sinuva MF Stent Users with no Prior use of Sinuva	Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Glaucoma		Single Sinuva MF Stent Users with no Prior use of Sinuva Excluding Cataracts		Repeat Sinuva MF Stent Users		Single Propel MF Stent Users	
	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Evidence of propel use	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Evidence of sinuva	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	82
No evidence of nasal polyps	1,462	N/A	1,464	N/A	1,463	N/A	1,444	N/A	10,009,963
Members with required post-index follow-up									
Had sufficient post-index continuous enrollment	0	1,387	0	1,349	0	1,526	0	35,774	0
Final cohort									
Number of members	N/A	1,387	N/A	1,349	N/A	1,526	N/A	35,774	N/A

[1]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date

Masked DP ID	DP Start Date	DP End Date[1]
DP01	01/01/2004	05/31/2021
DP02	01/01/2005	07/31/2022
DP03	01/01/2008	12/31/2021
DP04	01/01/2006	02/28/2022
DP05	01/01/2000	07/31/2022
DP06	01/01/2000	12/31/2020
DP07	01/01/2000	05/31/2022
DP08	01/01/2000	06/30/2020
DP09	01/01/2000	02/28/2021
DP10	01/01/2000	05/31/2021
DP11	01/01/2007	01/31/2022
DP12	01/01/2014	12/31/2018
DP13	01/01/2008	12/31/2021
DP14	01/01/2010	03/31/2022

[1]End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), and Healthcare Common Procedure Coding System, Level II (HCPCS) Procedure Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
	Propel		
0406T	Nasal endoscopy, surgical, ethmoid sinus, placement of drug eluting implant	Procedure	CPT-3
0407T	Nasal endoscopy, surgical, ethmoid sinus, placement of drug eluting implant; with polypectomy, biopsy or debridement	Procedure	CPT-3
31299	Unlisted procedure, accessory sinuses	Procedure	CPT-4
C2625	Stent, noncoronary, temporary, with delivery system	Procedure	HCPCS
J3490	Unclassified drugs	Procedure	HCPCS
S1090	Mometasone furoate sinus implant, 370 micrograms	Procedure	HCPCS
S1091	Stent, noncoronary, temporary, with delivery system (Propel)	Procedure	HCPCS
	Sinuva		
C9122	Mometasone furoate sinus implant, 10 micrograms (Sinuva)	Procedure	HCPCS
J7401	Mometasone furoate sinus implant, 10 mcg	Procedure	HCPCS
J7402	Mometasone furoate sinus implant, (Sinuva), 10 micrograms.	Procedure	HCPCS

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name
Propel	
mometasone furoate 0.37 MG	Propel
Sinuva	
mometasone furoate	Sinuva

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
	Nasal Polyp		
471	Nasal Polyps	Diagnosis	ICD-9-CM
471.0	Polyp of nasal cavity	Diagnosis	ICD-9-CM
471.1	Polypoid sinus degeneration	Diagnosis	ICD-9-CM
471.8	Other polyp of sinus	Diagnosis	ICD-9-CM
471.9	Unspecified nasal polyp	Diagnosis	ICD-9-CM
J33	Nasal polyp	Diagnosis	ICD-10-CM
J33.0	Polyp of nasal cavity	Diagnosis	ICD-10-CM
J33.1	Polypoid sinus degeneration	Diagnosis	ICD-10-CM
J33.8	Other polyp of sinus	Diagnosis	ICD-10-CM
J33.9	Nasal polyp, unspecified	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
	Propel		
0406T	Nasal endoscopy, surgical, ethmoid sinus, placement of drug eluting implant	Procedure	CPT-3
0407T	Nasal endoscopy, surgical, ethmoid sinus, placement of drug eluting implant; with polypectomy, biopsy or debridement	Procedure	CPT-3
31299	Unlisted procedure, accessory sinuses	Procedure	CPT-4
C2625	Stent, noncoronary, temporary, with delivery system	Procedure	HCPCS
J3490	Unclassified drugs	Procedure	HCPCS
S1090	Mometasone furoate sinus implant, 370 micrograms	Procedure	HCPCS
S1091	Stent, noncoronary, temporary, with delivery system (Propel)	Procedure	HCPCS
	Sinuva		
C9122	Mometasone furoate sinus implant, 10 micrograms (Sinuva)	Procedure	HCPCS
J7401	Mometasone furoate sinus implant, 10 mcg	Procedure	HCPCS
J7402	Mometasone furoate sinus implant, (Sinuva), 10 micrograms.	Procedure	HCPCS
	Glaucoma		
0123T	Fistulization of sclera for glaucoma, through ciliary body	Procedure	CPT-3
364.22	Glaucomatocyclitic crises	Diagnosis	ICD-9-CM
365	Glaucoma	Diagnosis	ICD-9-CM
365.0	Borderline glaucoma (glaucoma suspect)	Diagnosis	ICD-9-CM
365.00	Unspecified preglaucoma	Diagnosis	ICD-9-CM
365.01	Borderline glaucoma, open angle with borderline findings, low risk	Diagnosis	ICD-9-CM
365.02	Borderline glaucoma with anatomical narrow angle	Diagnosis	ICD-9-CM
365.03	Borderline glaucoma with steroid responders	Diagnosis	ICD-9-CM
365.04	Borderline glaucoma with ocular hypertension	Diagnosis	ICD-9-CM
365.05	Open angle with borderline findings, high risk	Diagnosis	ICD-9-CM
365.06	Primary angle closure without glaucoma damage	Diagnosis	ICD-9-CM
365.1	Open-angle glaucoma	Diagnosis	ICD-9-CM
365.10	Unspecified open-angle glaucoma	Diagnosis	ICD-9-CM
365.11	Primary open-angle glaucoma	Diagnosis	ICD-9-CM
365.12	Low tension open-angle glaucoma	Diagnosis	ICD-9-CM
365.13	Pigmentary open-angle glaucoma	Diagnosis	ICD-9-CM
365.14	Open-angle glaucoma of childhood	Diagnosis	ICD-9-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
365.15	Residual stage of open angle glaucoma	Diagnosis	ICD-9-CM
365.2	Primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.20	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.21	Intermittent angle-closure glaucoma	Diagnosis	ICD-9-CM
365.22	Acute angle-closure glaucoma	Diagnosis	ICD-9-CM
365.23	Chronic angle-closure glaucoma	Diagnosis	ICD-9-CM
365.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-9-CM
365.3	Corticosteroid-induced glaucoma	Diagnosis	ICD-9-CM
365.31	Corticosteroid-induced glaucoma, glaucomatous stage	Diagnosis	ICD-9-CM
365.32	Corticosteroid-induced glaucoma, residual stage	Diagnosis	ICD-9-CM
365.4	Glaucoma associated with congenital anomalies, dystrophies, and systemic syndromes	Diagnosis	ICD-9-CM
365.41	Glaucoma associated with chamber angle anomalies	Diagnosis	ICD-9-CM
365.42	Glaucoma associated with anomalies of iris	Diagnosis	ICD-9-CM
365.43	Glaucoma associated with other anterior segment anomalies	Diagnosis	ICD-9-CM
365.44	Glaucoma associated with systemic syndromes	Diagnosis	ICD-9-CM
365.5	Glaucoma associated with disorders of the lens	Diagnosis	ICD-9-CM
365.51	Phacolytic glaucoma	Diagnosis	ICD-9-CM
365.52	Pseudoexfoliation glaucoma	Diagnosis	ICD-9-CM
365.59	Glaucoma associated with other lens disorders	Diagnosis	ICD-9-CM
365.6	Glaucoma associated with other ocular disorders	Diagnosis	ICD-9-CM
365.60	Glaucoma associated with unspecified ocular disorder	Diagnosis	ICD-9-CM
365.61	Glaucoma associated with pupillary block	Diagnosis	ICD-9-CM
365.62	Glaucoma associated with ocular inflammations	Diagnosis	ICD-9-CM
365.63	Glaucoma associated with vascular disorders of eye	Diagnosis	ICD-9-CM
365.64	Glaucoma associated with tumors or cysts	Diagnosis	ICD-9-CM
365.65	Glaucoma associated with ocular trauma	Diagnosis	ICD-9-CM
365.7	Glaucoma stage	Diagnosis	ICD-9-CM
365.70	Glaucoma stage, unspecified	Diagnosis	ICD-9-CM
365.71	Mild stage glaucoma	Diagnosis	ICD-9-CM
365.72	Moderate stage glaucoma	Diagnosis	ICD-9-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
365.73	Severe stage glaucoma	Diagnosis	ICD-9-CM
365.74	Indeterminate stage glaucoma	Diagnosis	ICD-9-CM
365.8	Other specified forms of glaucoma	Diagnosis	ICD-9-CM
365.81	Hypersecretion glaucoma	Diagnosis	ICD-9-CM
365.82	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-9-CM
365.83	Aqueous misdirection	Diagnosis	ICD-9-CM
365.89	Other specified glaucoma	Diagnosis	ICD-9-CM
365.9	Unspecified glaucoma	Diagnosis	ICD-9-CM
377.14	Glaucomatous atrophy (cupping) of optic disc	Diagnosis	ICD-9-CM
66150	Fistulization of sclera for glaucoma; trephination with iridectomy	Procedure	CPT-4
66155	Fistulization of sclera for glaucoma; thermocauterization with iridectomy	Procedure	CPT-4
66160	Fistulization of sclera for glaucoma; sclerectomy with punch or scissors, with iridectomy	Procedure	CPT-4
66165	Fistulization of sclera for glaucoma; iridencleisis or iridotasis	Procedure	CPT-4
66170	Fistulization of sclera for glaucoma; trabeculectomy ab externo in absence of previous surgery	Procedure	CPT-4
66172	Fistulization of sclera for glaucoma; trabeculectomy ab externo with scarring from previous ocular surgery or trauma (includes injection of antifibrotic agents)	Procedure	CPT-4
66174	Transluminal dilation of aqueous outflow canal; without retention of device or stent	Procedure	CPT-4
66175	Transluminal dilation of aqueous outflow canal; with retention of device or stent	Procedure	CPT-4
66183	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, external approach	Procedure	CPT-4
66184	Revision of aqueous shunt to extraocular equatorial plate reservoir; without graft	Procedure	CPT-4
66185	Revision of aqueous shunt to extraocular equatorial plate reservoir; with graft	Procedure	CPT-4
66625	Iridectomy, with corneoscleral or corneal section; peripheral for glaucoma (separate procedure)	Procedure	CPT-4
66630	Iridectomy, with corneoscleral or corneal section; sector for glaucoma (separate procedure)	Procedure	CPT-4
66761	Iridotomy/iridectomy by laser surgery (eg, for glaucoma) (per session)	Procedure	CPT-4
92140	Provocative tests for glaucoma, with interpretation and report, without tonography	Procedure	CPT-4

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
92202	Ophthalmoscopy, extended; with drawing of optic nerve or macula (eg, for glaucoma, macular pathology, tumor) with interpretation and report, unilateral or bilateral	Procedure	CPT-4
G8306	Primary open-angle glaucoma patient with intraocular pressure above the target range goal documented to have received plan of care	Procedure	HCPCS
G8307	Primary open-angle glaucoma patient with intraocular pressure at or below goal, no plan of care necessary	Procedure	HCPCS
G8308	Primary open-angle glaucoma patient with intraocular pressure above the target range goal, and not documented to have received plan of care during the reporting year	Procedure	HCPCS
H26.23	Glaucomatous flecks (subcapsular)	Diagnosis	ICD-10-CM
H26.231	Glaucomatous flecks (subcapsular), right eye	Diagnosis	ICD-10-CM
H26.232	Glaucomatous flecks (subcapsular), left eye	Diagnosis	ICD-10-CM
H26.233	Glaucomatous flecks (subcapsular), bilateral	Diagnosis	ICD-10-CM
H26.239	Glaucomatous flecks (subcapsular), unspecified eye	Diagnosis	ICD-10-CM
H40	Glaucoma	Diagnosis	ICD-10-CM
H40.00	Preglaucoma, unspecified	Diagnosis	ICD-10-CM
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.01	Open angle with borderline findings, low risk	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.02	Open angle with borderline findings, high risk	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.03	Anatomical narrow angle	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.04	Steroid responder	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.05	Ocular hypertension	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.06	Primary angle closure without glaucoma damage	Diagnosis	ICD-10-CM
H40.061	Primary angle closure without glaucoma damage, right eye	Diagnosis	ICD-10-CM
H40.062	Primary angle closure without glaucoma damage, left eye	Diagnosis	ICD-10-CM
H40.063	Primary angle closure without glaucoma damage, bilateral	Diagnosis	ICD-10-CM
H40.069	Primary angle closure without glaucoma damage, unspecified eye	Diagnosis	ICD-10-CM
H40.1	Open-angle glaucoma	Diagnosis	ICD-10-CM
H40.10	Unspecified open-angle glaucoma	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.11	Primary open-angle glaucoma	Diagnosis	ICD-10-CM
H40.111	Primary open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.112	Primary open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.113	Primary open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.119	Primary open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.12	Low-tension glaucoma	Diagnosis	ICD-10-CM
H40.121	Low-tension glaucoma, right eye	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.122	Low-tension glaucoma, left eye	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.123	Low-tension glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.129	Low-tension glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.13	Pigmentary glaucoma	Diagnosis	ICD-10-CM
H40.131	Pigmentary glaucoma, right eye	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.132	Pigmentary glaucoma, left eye	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.133	Pigmentary glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.139	Pigmentary glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.14	Capsular glaucoma with pseudoexfoliation of lens	Diagnosis	ICD-10-CM
H40.141	Capsular glaucoma with pseudoexfoliation of lens, right eye	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.142	Capsular glaucoma with pseudoexfoliation of lens, left eye	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.143	Capsular glaucoma with pseudoexfoliation of lens, bilateral	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.149	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.15	Residual stage of open-angle glaucoma	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2	Primary angle-closure glaucoma	Diagnosis	ICD-10-CM
H40.20	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.21	Acute angle-closure glaucoma	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.22	Chronic angle-closure glaucoma	Diagnosis	ICD-10-CM
H40.221	Chronic angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.222	Chronic angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.223	Chronic angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.229	Chronic angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.23	Intermittent angle-closure glaucoma	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.3	Glaucoma secondary to eye trauma	Diagnosis	ICD-10-CM
H40.30	Glaucoma secondary to eye trauma, unspecified eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31	Glaucoma secondary to eye trauma, right eye	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32	Glaucoma secondary to eye trauma, left eye	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33	Glaucoma secondary to eye trauma, bilateral	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.4	Glaucoma secondary to eye inflammation	Diagnosis	ICD-10-CM
H40.40	Glaucoma secondary to eye inflammation, unspecified eye	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41	Glaucoma secondary to eye inflammation, right eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42	Glaucoma secondary to eye inflammation, left eye	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43	Glaucoma secondary to eye inflammation, bilateral	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.5	Glaucoma secondary to other eye disorders	Diagnosis	ICD-10-CM
H40.50	Glaucoma secondary to other eye disorders, unspecified eye	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51	Glaucoma secondary to other eye disorders, right eye	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52	Glaucoma secondary to other eye disorders, left eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53	Glaucoma secondary to other eye disorders, bilateral	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.6	Glaucoma secondary to drugs	Diagnosis	ICD-10-CM
H40.60	Glaucoma secondary to drugs, unspecified eye	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61	Glaucoma secondary to drugs, right eye	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62	Glaucoma secondary to drugs, left eye	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63	Glaucoma secondary to drugs, bilateral	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.8	Other glaucoma	Diagnosis	ICD-10-CM
H40.81	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.82	Hypersecretion glaucoma	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.83	Aqueous misdirection	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.51	Absolute glaucoma	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.23	Glaucomatous optic atrophy	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
	Cataract		
0289T	Corneal incisions in the donor cornea created using a laser, in preparation for penetrating or lamellar keratoplasty (List separately in addition to code for primary procedure)	Procedure	CPT-3
0290T	Corneal incisions in the recipient cornea created using a laser, in preparation for penetrating or lamellar keratoplasty (List separately in addition to code for primary procedure)	Procedure	CPT-3
085J3ZZ	Destruction of Right Lens, Percutaneous Approach	Procedure	ICD-10-PCS
085K3ZZ	Destruction of Left Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08BJ3ZZ	Excision of Right Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08BK3ZZ	Excision of Left Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08DJ3ZZ	Extraction of Right Lens, Percutaneous Approach	Procedure	ICD-10-PCS
08DK3ZZ	Extraction of Left Lens, Percutaneous Approach	Procedure	ICD-10-PCS
13.41	Phacoemulsification and aspiration of cataract	Procedure	ICD-9-CM
13.42	Mechanical phacofragmentation and aspiration of cataract by posterior route	Procedure	ICD-9-CM
13.43	Mechanical phacofragmentation and other aspiration of cataract	Procedure	ICD-9-CM
13.6	Other cataract extraction	Procedure	ICD-9-CM
13.64	Discission of secondary membrane (after cataract)	Procedure	ICD-9-CM
13.65	Excision of secondary membrane (after cataract)	Procedure	ICD-9-CM
13.66	Mechanical fragmentation of secondary membrane (after cataract)	Procedure	ICD-9-CM
13.69	Other cataract extraction	Procedure	ICD-9-CM
366	Cataract	Diagnosis	ICD-9-CM
366.00	Unspecified nonsenile cataract	Diagnosis	ICD-9-CM
366.01	Anterior subcapsular polar cataract, nonsenile	Diagnosis	ICD-9-CM
366.02	Posterior subcapsular polar cataract, nonsenile	Diagnosis	ICD-9-CM
366.03	Cortical, lamellar, or zonular cataract, nonsenile	Diagnosis	ICD-9-CM
366.04	Nuclear cataract, nonsenile	Diagnosis	ICD-9-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
366.09	Other and combined forms of nonsenile cataract	Diagnosis	ICD-9-CM
366.1	Senile cataract	Diagnosis	ICD-9-CM
366.10	Unspecified senile cataract	Diagnosis	ICD-9-CM
366.11	Pseudoexfoliation of lens capsule	Diagnosis	ICD-9-CM
366.12	Incipient cataract	Diagnosis	ICD-9-CM
366.13	Anterior subcapsular polar senile cataract	Diagnosis	ICD-9-CM
366.14	Posterior subcapsular polar senile cataract	Diagnosis	ICD-9-CM
366.15	Cortical senile cataract	Diagnosis	ICD-9-CM
366.16	Nuclear sclerosis	Diagnosis	ICD-9-CM
366.17	Total or mature senile cataract	Diagnosis	ICD-9-CM
366.18	Hypermature senile cataract	Diagnosis	ICD-9-CM
366.19	Other and combined forms of senile cataract	Diagnosis	ICD-9-CM
366.2	Traumatic cataract	Diagnosis	ICD-9-CM
366.20	Unspecified traumatic cataract	Diagnosis	ICD-9-CM
366.21	Localized traumatic opacities of cataract	Diagnosis	ICD-9-CM
366.22	Total traumatic cataract	Diagnosis	ICD-9-CM
366.23	Partially resolved traumatic cataract	Diagnosis	ICD-9-CM
366.3	Cataract secondary to ocular disorders	Diagnosis	ICD-9-CM
366.30	Unspecified cataracta complicata	Diagnosis	ICD-9-CM
366.31	Cataract secondary to glaucomatous flecks (subcapsular)	Diagnosis	ICD-9-CM
366.32	Cataract in inflammatory ocular disorders	Diagnosis	ICD-9-CM
366.33	Cataract with ocular neovascularization	Diagnosis	ICD-9-CM
366.34	Cataract in degenerative ocular disorders	Diagnosis	ICD-9-CM
366.4	Cataract associated with other disorders	Diagnosis	ICD-9-CM
366.50	Unspecified after-cataract	Diagnosis	ICD-9-CM
366.52	Other after-cataract, not obscuring vision	Diagnosis	ICD-9-CM
366.53	After-cataract, obscuring vision	Diagnosis	ICD-9-CM
366.8	Other cataract	Diagnosis	ICD-9-CM
366.9	Unspecified cataract	Diagnosis	ICD-9-CM
65710	Keratoplasty (corneal transplant); anterior lamellar	Procedure	CPT-4
65720	Keratoplasty (corneal Transplant), Lamellar	Procedure	CPT-4

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
65725	Keratoplasty (corneal Transplant), Lamellar	Procedure	CPT-4
65730	Keratoplasty (corneal transplant); penetrating (except in aphakia or pseudophakia)	Procedure	CPT-4
65740	Keratoplasty (corneal Transplant), Penetrating (except In	Procedure	CPT-4
65745	Keratoplasty (corneal Transplant), Penetrating (except In	Procedure	CPT-4
65750	Keratoplasty (corneal transplant); penetrating (in aphakia)	Procedure	CPT-4
65755	Keratoplasty (corneal transplant); penetrating (in pseudophakia)	Procedure	CPT-4
65756	Keratoplasty (corneal transplant); endothelial	Procedure	CPT-4
65767	Epikeratoplasty	Procedure	CPT-4
65855	Trabeculoplasty by laser surgery	Procedure	CPT-4
65860	Severing adhesions of anterior segment, laser technique (separate procedure)	Procedure	CPT-4
66820	Discission of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid); stab incision technique (Ziegler or Wheeler knife)	Procedure	CPT-4
66821	Discission of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid); laser surgery (eg, YAG laser) (1 or more stages)	Procedure	CPT-4
66825	Repositioning of intraocular lens prosthesis, requiring an incision (separate procedure)	Procedure	CPT-4
66830	Removal of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid) with corneo-scleral section, with or without iridectomy (iridocapsulotomy, iridocapsulectomy)	Procedure	CPT-4
66840	Removal of lens material; aspiration technique, 1 or more stages	Procedure	CPT-4
66850	Removal of lens material; phacofragmentation technique (mechanical or ultrasonic) (eg, phacoemulsification), with aspiration	Procedure	CPT-4
66852	Removal of lens material; pars plana approach, with or without vitrectomy	Procedure	CPT-4
66920	Removal of lens material; intracapsular	Procedure	CPT-4
66930	Removal of lens material; intracapsular, for dislocated lens	Procedure	CPT-4
66940	Removal of lens material; extracapsular (other than 66840, 66850, 66852)	Procedure	CPT-4

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
66982	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage	Procedure	CPT-4
66983	Intracapsular cataract extraction with insertion of intraocular lens prosthesis (1 stage procedure)	Procedure	CPT-4
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification)	Procedure	CPT-4
H25.011	Cortical age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.012	Cortical age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.013	Cortical age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.019	Cortical age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.031	Anterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.032	Anterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.033	Anterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.039	Anterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.041	Posterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.042	Posterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.043	Posterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.049	Posterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.091	Other age-related incipient cataract, right eye	Diagnosis	ICD-10-CM
H25.092	Other age-related incipient cataract, left eye	Diagnosis	ICD-10-CM
H25.093	Other age-related incipient cataract, bilateral	Diagnosis	ICD-10-CM
H25.099	Other age-related incipient cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.10	Age-related nuclear cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.11	Age-related nuclear cataract, right eye	Diagnosis	ICD-10-CM
H25.12	Age-related nuclear cataract, left eye	Diagnosis	ICD-10-CM
H25.13	Age-related nuclear cataract, bilateral	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H25.20	Age-related cataract, morgagnian type, unspecified eye	Diagnosis	ICD-10-CM
H25.21	Age-related cataract, morgagnian type, right eye	Diagnosis	ICD-10-CM
H25.22	Age-related cataract, morgagnian type, left eye	Diagnosis	ICD-10-CM
H25.23	Age-related cataract, morgagnian type, bilateral	Diagnosis	ICD-10-CM
H25.811	Combined forms of age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.812	Combined forms of age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.813	Combined forms of age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.819	Combined forms of age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.89	Other age-related cataract	Diagnosis	ICD-10-CM
H25.9	Unspecified age-related cataract	Diagnosis	ICD-10-CM
H26.001	Unspecified infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.002	Unspecified infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.003	Unspecified infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.009	Unspecified infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.011	Infantile and juvenile cortical, lamellar, or zonular cataract, right eye	Diagnosis	ICD-10-CM
H26.012	Infantile and juvenile cortical, lamellar, or zonular cataract, left eye	Diagnosis	ICD-10-CM
H26.013	Infantile and juvenile cortical, lamellar, or zonular cataract, bilateral	Diagnosis	ICD-10-CM
H26.019	Infantile and juvenile cortical, lamellar, or zonular cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.031	Infantile and juvenile nuclear cataract, right eye	Diagnosis	ICD-10-CM
H26.032	Infantile and juvenile nuclear cataract, left eye	Diagnosis	ICD-10-CM
H26.033	Infantile and juvenile nuclear cataract, bilateral	Diagnosis	ICD-10-CM
H26.039	Infantile and juvenile nuclear cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.041	Anterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.042	Anterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.043	Anterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.049	Anterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.051	Posterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.052	Posterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.053	Posterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.059	Posterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.061	Combined forms of infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H26.062	Combined forms of infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.063	Combined forms of infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.069	Combined forms of infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.09	Other infantile and juvenile cataract	Diagnosis	ICD-10-CM
H26.101	Unspecified traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.102	Unspecified traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.103	Unspecified traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.109	Unspecified traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.111	Localized traumatic opacities, right eye	Diagnosis	ICD-10-CM
H26.112	Localized traumatic opacities, left eye	Diagnosis	ICD-10-CM
H26.113	Localized traumatic opacities, bilateral	Diagnosis	ICD-10-CM
H26.119	Localized traumatic opacities, unspecified eye	Diagnosis	ICD-10-CM
H26.121	Partially resolved traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.122	Partially resolved traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.123	Partially resolved traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.129	Partially resolved traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.131	Total traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.132	Total traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.133	Total traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.139	Total traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.20	Unspecified complicated cataract	Diagnosis	ICD-10-CM
H26.211	Cataract with neovascularization, right eye	Diagnosis	ICD-10-CM
H26.212	Cataract with neovascularization, left eye	Diagnosis	ICD-10-CM
H26.213	Cataract with neovascularization, bilateral	Diagnosis	ICD-10-CM
H26.219	Cataract with neovascularization, unspecified eye	Diagnosis	ICD-10-CM
H26.221	Cataract secondary to ocular disorders (degenerative) (inflammatory), right eye	Diagnosis	ICD-10-CM
H26.222	Cataract secondary to ocular disorders (degenerative) (inflammatory), left eye	Diagnosis	ICD-10-CM
H26.223	Cataract secondary to ocular disorders (degenerative) (inflammatory), bilateral	Diagnosis	ICD-10-CM
H26.229	Cataract secondary to ocular disorders (degenerative) (inflammatory), unspecified eye	Diagnosis	ICD-10-CM
H26.231	Glaucomatous flecks (subcapsular), right eye	Diagnosis	ICD-10-CM

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Procedure and Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
H26.232	Glaucomatous flecks (subcapsular), left eye	Diagnosis	ICD-10-CM
H26.233	Glaucomatous flecks (subcapsular), bilateral	Diagnosis	ICD-10-CM
H26.239	Glaucomatous flecks (subcapsular), unspecified eye	Diagnosis	ICD-10-CM
H26.30	Drug-induced cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.31	Drug-induced cataract, right eye	Diagnosis	ICD-10-CM
H26.32	Drug-induced cataract, left eye	Diagnosis	ICD-10-CM
H26.33	Drug-induced cataract, bilateral	Diagnosis	ICD-10-CM
H26.40	Unspecified secondary cataract	Diagnosis	ICD-10-CM
H26.491	Other secondary cataract, right eye	Diagnosis	ICD-10-CM
H26.492	Other secondary cataract, left eye	Diagnosis	ICD-10-CM
H26.493	Other secondary cataract, bilateral	Diagnosis	ICD-10-CM
H26.499	Other secondary cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.8	Other specified cataract	Diagnosis	ICD-10-CM
H26.9	Unspecified cataract	Diagnosis	ICD-10-CM
H28	Cataract in diseases classified elsewhere	Diagnosis	ICD-10-CM

Appendix F. Generic and Brand Names of Medical Products Used to Define Exclusion Criteria in this Request

Generic Name	Brand Name
Propel	
mometasone furoate 0.37 MG	Propel
Sinuva	
mometasone furoate	Sinuva
Glaucoma	
acetylcholine chloride	Miochol-E
apraclonidine HCl	Iopidine
apraclonidine HCl	apraclonidine
betaxolol HCl	Betoptic S
betaxolol HCl	betaxolol
bimatoprost	Durysta
bimatoprost	Lumigan
bimatoprost	bimatoprost
brimonidine tartrate	Alphagan P
brimonidine tartrate	Lumify
brimonidine tartrate	brimonidine
brimonidine tartrate/dorzolamide HCl/PF	brimonidine-dorzolamide (PF)
brimonidine tartrate/timolol maleate	Combigan
brimonidine tartrate/timolol maleate	brimonidine-timolol
brinzolamide	Azopt
brinzolamide	brinzolamide
brinzolamide/brimonidine tartrate	Simbrinza
carbachol	Miostat
carteolol HCl	carteolol
dorzolamide HCl	Trusopt
dorzolamide HCl	dorzolamide
dorzolamide HCl/PF	dorzolamide (PF)
dorzolamide HCl/timolol maleate	Cosopt
dorzolamide HCl/timolol maleate	dorzolamide-timolol
dorzolamide HCl/timolol maleate/PF	Cosopt (PF)
dorzolamide HCl/timolol maleate/PF	dorzolamide-timolol (PF)
echothiophate iodide	Phospholine Iodide
latanoprost	Xalatan
latanoprost	Xelpros
latanoprost	latanoprost
latanoprost/PF	latanoprost (PF)
latanoprostene bunod	Vyzulta
levobunolol HCl	Betagan
levobunolol HCl	levobunolol
metipranolol	metipranolol
netarsudil mesylate	Rhopressa
netarsudil mesylate/latanoprost	Rocklatan
pilocarpine HCl	Isopto Carpine
pilocarpine HCl	Vuity
pilocarpine HCl	pilocarpine HCl
tafluprost/PF	Zioptan (PF)
timolol	Betimol

Appendix F. Generic and Brand Names of Medical Products Used to Define Exclusion Criteria in this Request

Generic Name	Brand Name
timolol maleate	Istalol
timolol maleate	Timoptic
timolol maleate	Timoptic-XE
timolol maleate	timolol maleate
timolol maleate/PF	Timoptic Ocudose (PF)
timolol maleate/PF	timolol maleate (PF)
timolol maleate/brimonidine tartrate/dorzolamide HCl/PF	timolol-brimonidi-dorzolam(PF)
timolol maleate/dorzolamide HCl/latanoprost/PF	timolol-dorzolamid-latanop(PF)
timolol maleate/latanoprost/PF	timolol-latanoprost(PF)
travoprost	Travatan Z
travoprost	travoprost
travoprost (benzalkonium)	travoprost (benzalkonium)
unoprostone isopropyl	Rescula

Appendix G. Specifications for Request: cder_mpl1r_wp227

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [version 11.4.0] , a rerun of the request cder_mpl1r_wp207, to determine the capture of Sinuva stent use in the Sentinel Distributed Database (SDD). This is a Type 5 request.

Query Period: 01/01/2016 - Most recently available data
Enrollment Requirement: 183 days
Enrollment Gap: 45 days
Coverage Requirement: Medical and Drug Coverage
Age Groups: 00-01,02-04,05-09,10-14,15-18,19-21,22-44,45-64,65-74,75+ years
Sex: M, F
Results Stratified by: Age, Sex, Year
Envelope macro: No reclassification on inpatient Adate

		Exposure														
	cida group	Index Exposure	Incidence w/ respect to:	Washout (Days)	Episode Gap	Episode Gap Type[1]	Episode Extension	Minimum Episode Duration	Days Supply	Exclude evidence of days supply if exposure washout includes dispensings	Cohort Definition	Censor due to Evidence of:	Pre-Existing Conditions	Include/Exclude	Lookback Period	Include/ Exclude	Lookback Period
1	Sinu_Sing	Sinuva: Single Implant	Stent procedures/NDCs: Propel or Sinuva	183	0	F	0	1	1	*Washout lookback period should look for days supply (i.e. DATEONLY = N)	04	*Death; *Data Partner End Date; *Query End Date; *Disenrollment	Nasal polyp diagnosis	Include	-183, -1	No Exclude Glaucoma or Cataracts	-183, -1
2	Sinu_Sing_ExlGlauc	Sinuva: Single Implant	Stent procedures/NDCs: Propel or Sinuva	183	0	F	0	1	1	*Washout lookback period should look for days supply (i.e. DATEONLY = N)	04	*Death; *Data Partner End Date; *Query End Date; *Disenrollment	Nasal polyp diagnosis	Include	-183, -1	Exclude glucoma	-183, -1
3	Sinu_Sing_ExclCat	Sinuva: Single Implant	Stent procedures/NDCs: Propel or Sinuva	183	0	F	0	1	1	*Washout lookback period should look for days supply (i.e. DATEONLY = N)	04	*Death; *Data Partner End Date; *Query End Date; *Disenrollment	Nasal polyp diagnosis	Include	-183, -1	Exclude cataract	-183, -1
4	Sinu_Sing_is	Sinuva: Single Implant	Stent procedures: Sinuva	183	0	F	0	1	1	*Washout lookback period should look for days supply (i.e. DATEONLY = N)	04	*Death; *Data Partner End Date; *Query End Date; *Disenrollment	Nasal polyp diagnosis	Include	-183, -1	No Exclude	-183, -1
5	Sinu_Sing_is_ExclGlauc	Sinuva: Single Implant	Stent procedures: Sinuva	183	0	F	0	1	1	*Washout lookback period should look for days supply (i.e. DATEONLY = N)	04	*Death; *Data Partner End Date; *Query End Date; *Disenrollment	Nasal polyp diagnosis	Include	-183, -1	Exclude glucoma	-183, -1
6	Sinu_Sing_is_ExclCat	Sinuva: Single Implant	Stent procedures: Sinuva	183	0	F	0	1	1	*Washout lookback period should look for days supply (i.e. DATEONLY = N)	04	*Death; *Data Partner End Date; *Query End Date; *Disenrollment	Nasal polyp diagnosis	Include	-183, -1	Exclude cataract	-183, -1
7	Sinu_Rep_0Days	Sinuva: Repeat Implant (1 day supply, 0 days allowed gap)	--	0	0	F	0	1	1	*Washout lookback period should look for days supply (i.e. DATEONLY = N)	04	*Death; *Data Partner End Date; *Query End Date; *Disenrollment	Nasal polyp diagnosis	Include	-183, -1	No Exclude	-183, -1

Appendix G. Specifications for Request: cder_mpl1r_wp227

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [version 11.4.0] , a rerun of the request cder_mpl1r_wp207, to determine the capture of Sinuva stent use in the Sentinel Distributed Database (SDD). This is a Type 5 request.

Query Period: 01/01/2016 - Most recently available data
Enrollment Requirement: 183 days
Enrollment Gap: 45 days
Coverage Requirement: Medical and Drug Coverage
Age Groups: 00-01,02-04,05-09,10-14,15-18,19-21,22-44,45-64,65-74,75+ years
Sex: M, F
Results Stratified by: Age, Sex, Year
Envelope macro: No reclassification on inpatient Adate

		Exposure															
	cida group	Index Exposure	Incidence w/ respect to:	Washout (Days)	Episode Gap	Episode Gap Type[1]	Episode Extension	Minimum Episode Duration	Days Supply	Exclude evidence of days supply if exposure washout includes dispensings	Cohort Definition	Censor due to Evidence of:	Pre-Existing Conditions	Include/Exclude	Lookback Period	Include/ Exclude	Lookback Period
8	Prop_Sing	Propel: Single Implant	Stent procedures: Propel or Sinuva	183	0	F	0	1	1	*Washout lookback period should look for days supply (i.e. DATEONLY = N)	04	*Death; *Data Partner End Date; *Query End Date; *Disenrollment	Nasal polyp diagnosis	Include	-183, -1	No Exclude	-183, -1

[1]Episode Gap Type F: Fixed episode gap
ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360. NDC codes are checked against First Data Bank's "National Drug Data File (NDDF®) Plus."